Xilio Therapeutics, Inc. (XLO): Shareholders' Equity
$35.27M
As of 2025-12-31
$72.26M
As of 2026-06-30
-30.6%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $35.27M | +100.4% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $17.60M | -52.2% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $36.83M | -65.1% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $105.65M | -43.0% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $185.43M | n/m | 2023-03-02, Balance as of period end |
| 2020-12-31 | -$83.29M | n/a | 2022-03-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $35.27M | +100.4% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $17.67M | -13.0% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $24.88M | +8.9% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$33.66M | n/m |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $518.36M | +147.4% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $10.48M | +136.4% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $381.93M | -9.1% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $614.71M | -9.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$122.76M | n/m |
Compare XLO, INBP, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗